Clinical trial
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
NCT00217763 · Bellus Health Inc. - a GSK company, Industry · Unknown status
Key facts
| NCT number | NCT00217763 |
|---|---|
| Title | European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients |
| Official title | A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Bellus Health Inc. - a GSK company, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | 3APS |
| Enrollment | 930 |
| Start date | Sep 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 10, 2007 |
| Countries | Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: